
    
      CD34+ cells will be isolated from mobilized PBMC of HIV patients. The cells will be
      lentivirally transduced with multiplexed shRNAs in the same vector that target CCR5 and HIV
      genome. Such modified cells will be infused back to the patients who have received bulsufan
      preconditioning before infusion. The patients will then be evaluated for efficacy and safety.
    
  